The ratio of matrix metalloproteinase to E-cadherin expression: A pilot study to assess mRNA and protein expression among African American prostate cancer patients

Prostate

Volumn 68, Issue 13, 2008, Pages 1467-1476

  Pettaway, Curtis A ^a   Song, Renduo ^a   Wang, Xuemei ^a   Sanchez Ortiz, Ricardo ^b   Spiess, Philippe E ^a   Strom, Sara ^a   Troncoso, Patricia ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

African American; E cadherin; Matrix metalloproteinase; Prostate cancer; Radical prostatectomy

Indexed keywords

FORMALDEHYDE; GELATINASE A; GELATINASE B; MESSENGER RNA; MONOCLONAL ANTIBODY; PARAFFIN; UVOMORULIN; CADHERIN;

AFRICAN AMERICAN; ARTICLE; BIOTINYLATION; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COLORIMETRY; DISEASE COURSE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; OLIGONUCLEOTIDE PROBE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; STAINING; ADENOCARCINOMA; COHORT ANALYSIS; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROGNOSIS; PROSTATE TUMOR;

ADENOCARCINOMA; AFRICAN AMERICANS; CADHERINS; COHORT STUDIES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PILOT PROJECTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 50949100944     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20812     Document Type: Article

References (51)

1. Jemal A, Seigal R, Ward E, Yongping H, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Sakr WA, Grignon DJ, Haas GP, Schomer KL, Heilbrun LK, Cassin BJ, Powell J, Montie JA, Pontes JE. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995;191:838-841.
3. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: A comparative study based on radical prostatectomy specimens. J Urol 1998;160:437-442.
4. Tiguert R, Gheiler EL, Tefilli MV, Banerjee M, Grignon DJ, Sakr W, Wood DP Jr, Powell IJ, Pontes JE. Racial differences and prognostic significance of tumor location in radical prostatectomy specimens. Prostate 1998;37:230-235.
5. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African American men with nonpalpable prostate cancer exhibit greater tumor volume than matched Caucasian men. Cancer 2006;107:75-82.
6. Moul JW, Connelly RR, Mooneyhan RM, Zhang W, Sesterhenn IA, Mostofi FK, McLeod DG. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 1999;162:394-397.
7. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-889.
8. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.
9. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997;57:1020-1022.
10. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, Reichardt JK. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk. Prostate 1997;33:9-12.
11. Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V. Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism 2001;50:1242-1247.
12. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a CYP3A4 Variant and Clinical Presentation in African American Prostate Cancer Patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-905.
13. Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghot UC, Adams-Campbell L, Isaacs W, Dunston GM. CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001;10:943-947.
14. Irvine RA, Y MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937.
15. Strom SS, Gu Y, Zhang H, Zhang H, Tron Coso P, Babarian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 2004;60:343-3351.
16. Tricoli JV, Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 1999;54:178-182.
17. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-1110.
18. Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE, Tricoli JV. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology 2001;58:614-618.
19. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas utilizing orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-1636.
20. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Fidler IJ. In situ mRNA hybridization technique for analysis of metastasis-related genes in human prostate carcinoma cells. Am J Pathol 1997;150:1571-1582.
21. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpressed vascular endothelial growth factor. Clin Cancer Res 1999;5:783-789.
22. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104-2119.
23. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. Relative expression of Type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000;6:2295-2308.
24. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguish organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 2003;9:2185-2194.
25. Ayala AG, Ro JY, Babaian RJ, Troncoso P, Grignon D. The prostatic capsule: Does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 1989;13:21-27.
26. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability. J Urol 1995;154:1808.
27. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW, AJCC cancer staging manual. 5th edition. Philadelphia: Lippincott-Raven; 1997. pp. 121-126.
28. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-138.
29. Park C-S, Manahan LJ, Brigati DJ. Automated molecular pathology: One hour in situ DNA hybridization. J Histotechnol 1991;14:219-229.
30. Bucana CD, Radinsky R, Dong Z, Sanchez R, Brigati DJ, Fidler IJ. A rapid colorimetric in situ mRNA hybridization technique using hyper biotinylated oligonucleotide probes for analysis of mdr-1 in mouse colon carcinoma cells. J Histochem Cytochem 1993;41:499-506.
31. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, Shaheen RM, Bucana CD, Ellis LM. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001;61:1255-1259.
32. Brieman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Monterrey, California: Wadsworth & Brooks/Cole; 1984.
33. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Statist Assoc 1958;53:457-481.
34. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;60:163-170.
35. Cox DR. Regression models and life tables (with discussion). J R Statistical Soc B 1972;34:187-220.
36. Venables WN, Ripley BD. Modern applied statistics with splus. 3rd edition. New York: Springer; 1999.
37. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase-2 (MMP-2): Expression associated with human prostate cancer progression. Oncol Res 1996;8:69-75.
38. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer. Cancer Res 2003;63:8511-8515.
39. Still K, Robson CN, Autzen Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in benign and malignant prostatic tissue. Prostate 2000;42:8-25.
40. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
41. Richmond PJM, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and E-catenin expression in prostate cancer: Correlation with patient survival. Cancer Res 1997;57:3189-3193.
42. Luo J, Lubaroff DM, Hendrix MJC. Suppression of prostate cancer invasive phenotype and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999;59:3552-3556.
43. DeMarzo A, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707-713.
44. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-668.
45. Mebane C, Gibbs T, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc 1990;82:782-788.
46. Hoffman RM, Gilliland FD, Eley JW, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hemilton AS, Hunt WC, Potosky AL. Racial and ethnic differences in advanced-stage prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93:388-395.
47. Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: Sociology or biology? Prostate 2005;62:243-252.
48. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornguist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. JNCI 2001;93(14):1054-1061.
49. Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003;4(4):523-538.
50. Kattan MW. Judging new markers by their ability to improve predictive accuracy. JNCI 2003;95(9):634-635.
51. Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003;170(6 Pt 2):S6-S9; discussion S10.